Decoration of the enterococcal polysaccharide antigen EPA is essential for virulence, cell surface charge and interaction with effectors of the innate immune system.
Animals
Antigens, Surface
/ genetics
Antimicrobial Cationic Peptides
/ pharmacology
Bacterial Proteins
/ genetics
Enterococcus faecalis
/ genetics
Gram-Positive Bacterial Infections
/ immunology
Muramidase
/ immunology
Mutagenesis
Mutation
Polysaccharides
/ immunology
Virulence
Zebrafish
/ growth & development
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
27
11
2018
accepted:
26
03
2019
entrez:
4
5
2019
pubmed:
3
5
2019
medline:
8
11
2019
Statut:
epublish
Résumé
Enterococcus faecalis is an opportunistic pathogen with an intrinsically high resistance to lysozyme, a key effector of the innate immune system. This high level of resistance requires a complex network of transcriptional regulators and several genes (oatA, pgdA, dltA and sigV) acting synergistically to inhibit both the enzymatic and cationic antimicrobial peptide activities of lysozyme. We sought to identify novel genes modulating E. faecalis resistance to lysozyme. Random transposon mutagenesis carried out in the quadruple oatA/pgdA/dltA/sigV mutant led to the identification of several independent insertions clustered on the chromosome. These mutations were located in a locus referred to as the enterococcal polysaccharide antigen (EPA) variable region located downstream of the highly conserved epaA-epaR genes proposed to encode a core synthetic machinery. The epa variable region was previously proposed to be responsible for EPA decorations, but the role of this locus remains largely unknown. Here, we show that EPA decoration contributes to resistance towards charged antimicrobials and underpins virulence in the zebrafish model of infection by conferring resistance to phagocytosis. Collectively, our results indicate that the production of the EPA rhamnopolysaccharide backbone is not sufficient to promote E. faecalis infections and reveal an essential role of the modification of this surface polymer for enterococcal pathogenesis.
Identifiants
pubmed: 31048927
doi: 10.1371/journal.ppat.1007730
pii: PPATHOGENS-D-18-02275
pmc: PMC6497286
doi:
Substances chimiques
Antigens, Surface
0
Antimicrobial Cationic Peptides
0
Bacterial Proteins
0
Polysaccharides
0
Muramidase
EC 3.2.1.17
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1007730Subventions
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/R000727/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N02995X/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/M011151/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N02995X/1
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1574-9
pubmed: 11830672
Clin Chim Acta. 1974 Dec 17;57(3):205-9
pubmed: 4434640
J Bacteriol. 1992 Sep;174(17):5633-8
pubmed: 1324906
Infect Immun. 2002 Apr;70(4):2010-5
pubmed: 11895965
Gene. 1989 Apr 15;77(1):51-9
pubmed: 2744487
J Infect Dis. 2009 Aug 1;200(3):417-20
pubmed: 19545208
J Biol Chem. 2012 Nov 2;287(45):37769-77
pubmed: 22908219
Infect Immun. 2013 Nov;81(11):4271-9
pubmed: 24002065
PLoS Pathog. 2017 Jul 24;13(7):e1006526
pubmed: 28742152
J Biol Chem. 2008 Jul 11;283(28):19845-53
pubmed: 18490448
Appl Environ Microbiol. 2008 Aug;74(15):4764-7
pubmed: 18539809
Proc Natl Acad Sci U S A. 1978 Jul;75(7):3479-83
pubmed: 98769
J Bacteriol. 2006 Dec;188(24):8513-9
pubmed: 17041059
Infect Immun. 2006 Jul;74(7):4164-71
pubmed: 16790791
PLoS Pathog. 2015 Jun 12;11(6):e1004911
pubmed: 26067254
J Bacteriol. 2005 Feb;187(3):1022-35
pubmed: 15659680
Nat Rev Microbiol. 2012 Mar 16;10(4):266-78
pubmed: 22421879
Acta Ophthalmol (Copenh). 1984 Dec;62(6):932-8
pubmed: 6395619
Infect Immun. 2007 Nov;75(11):5390-8
pubmed: 17785473
PLoS One. 2010 Mar 11;5(3):e9658
pubmed: 20300180
Front Microbiol. 2016 May 26;7:788
pubmed: 27303380
Infect Immun. 2009 Sep;77(9):3759-67
pubmed: 19581393
J Bacteriol. 2009 Oct;191(20):6203-10
pubmed: 19684130
PLoS Pathog. 2007 Jul 27;3(7):e102
pubmed: 17676995
Vaccine. 2002 Jun 7;20(19-20):2474-84
pubmed: 12057602
J Biosci. 2010 Mar;35(1):127-60
pubmed: 20413917
Infect Immun. 2017 Dec 19;86(1):
pubmed: 29038125
Antimicrob Agents Chemother. 2015 Jul;59(7):4094-105
pubmed: 25918141
J Biol Chem. 2001 Nov 23;276(47):43767-74
pubmed: 11560930
Free Radic Biol Med. 2017 Apr;105:3-15
pubmed: 27810411
NPJ Biofilms Microbiomes. 2017 Jun 30;3:15
pubmed: 28685097
Appl Environ Microbiol. 1999 Dec;65(12):5328-33
pubmed: 10583984
J Infect Dis. 2015 Jan 1;211(1):62-71
pubmed: 25035517
mBio. 2012 Mar 01;3(1):e00318-11
pubmed: 22354958
Infect Immun. 2000 Feb;68(2):815-23
pubmed: 10639451
J Bacteriol. 2012 Nov;194(22):6066-73
pubmed: 22961856
PLoS Genet. 2012 Jun;8(6):e1002804
pubmed: 22761597
J Bacteriol. 2004 Dec;186(23):7951-8
pubmed: 15547267
Anal Biochem. 1986 Sep;157(2):367-74
pubmed: 3777441